Medical panel suggests bulk purchase of influenza drug was a waste of money, but others caution against dropping anti-pandemic strategy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Jefferson, T. et al. Br. Med. J. 339, b5106 (2009).
Jefferson, T. et al. Cochrane Database of Systematic Reviews CD008965 (2014).
Kaiser, L. et al. Arch. Intern. Med. 163, 1667-1672 (2003).
Hsu, J. et al. Ann. Intern. Med. 3, 512-524 (2012).
Muthuri, S. et al. Lancet Respir. Med. http://dx.doi.org/10.1016/S2213-2600(14)70041-4 (2014).
Related links
Related links
Related links in Nature Research
Secrets of trial data revealed 2013-Oct-08
Drug-company data vaults to be opened 2013-Mar-27
Avian flu special: What's in the medicine cabinet? 2005-May-25
Related external links
The British Medical Journal and Cochrane Collaboration's Tamiflu campaign
Rights and permissions
About this article
Cite this article
Van Noorden, R. Report disputes benefit of stockpiling Tamiflu. Nature (2014). https://doi.org/10.1038/nature.2014.15022
Published:
DOI: https://doi.org/10.1038/nature.2014.15022